SS Innovations International (NASDAQ: SSII), a developer of surgical robotic technologies, announced the appointment of Sarah M. Romano as chief financial officer, effective Aug. 3, 2026. Romano, who is based in the United States, brings more than two decades of finance leadership experience in the medical technology and life sciences sectors. She will help lead the company’s financial operations as it advances its global expansion strategy, including pursuit of U.S. FDA approval for its SSi Mantra surgical robotic system.
Most recently, Romano served as chief financial officer of Vicarious Surgical, where she led financial and operational initiatives to reduce cash burn, strengthen the balance sheet and support strategic objectives. She previously held CFO roles at Entero Therapeutics and Kiora Pharmaceuticals, raising more than $100 million through public and private financings while overseeing strategic transactions, SEC reporting and investor relations.
The appointment comes at a critical time for SS Innovations as the company seeks to broaden the global footprint of its surgical robotic solutions. The SSi Mantra system, designed to be user-friendly and cost-effective, aims to make robotic surgery more accessible worldwide. Romano’s experience in raising capital and managing financial operations is expected to be instrumental in navigating the regulatory pathway and scaling commercialization efforts.
For more details, the full press release is available at https://ibn.fm/pAqlP.
SS Innovations International, Inc. develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. The Company’s product range includes its proprietary “SSi Mantra” surgical robotic system and its comprehensive suite of “SSi Mudra” surgical instruments, which support a variety of surgical robotic procedures including cardiac surgery. An American company headquartered in India, SS Innovations plans to expand the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions.
Forward-looking statements in this article are subject to risks and uncertainties as detailed in the Company’s filings with the SEC. Please see full terms of use and disclaimers on the InvestorBrandNetwork website at http://IBN.fm/Disclaimer.
